Fig. 8From: Cost utility analysis of cryopreserved amniotic membrane versus topical cyclosporine for the treatment of moderate to severe dry eye syndromeSensitivity analysis showing that if the probability of a positive clinical response to Prokera is <54% then Cyclosporine A (Restasis) becomes the less expensive optionBack to article page